FDA: Smoking Cessation Drug Tied to Cardiac Issues

Varenicline (Chantix) associated with small but increased risk of cardiac problems

FRIDAY, June 17 (HealthDay News) -- The U.S. Food and Drug Administration has warned consumers and health care professionals that varenicline (Chantix) may be associated with a small but increased risk of cardiovascular adverse events in individuals with cardiovascular disease.

Varenicline is considered a smoking cessation aid and has been on the market since 2006. The new warning is based on the FDA's review of data from a study that involved 700 smokers with cardiovascular disease who were undergoing treatment with varenicline or placebo. The data revealed a small but statistically significant increased risk of angina pectoris, non-fatal myocardial infarction, need for coronary revascularization, and new diagnosis of peripheral vascular disease or admission for a procedure for the treatment of peripheral vascular disease in individuals taking the drug.

The FDA recommends that individuals undergoing treatment with varenicline should contact their health care provider if they experience new or worsening symptoms of cardiovascular disease. The FDA is continuing to evaluate the cardiovascular safety of varenicline and has requested that Pfizer, the manufacturer of the drug, conduct a large meta-analysis of previous randomized, placebo-controlled trials involving the drug. The FDA will provide an update to consumers and health care professionals when additional data becomes available.

According to the FDA, "health care professionals should be aware that smoking is an independent and major risk factor for cardiovascular disease, and smoking cessation is of particular importance in this patient population. The known benefits of Chantix should be weighed against its potential risks when deciding to use the drug in smokers with cardiovascular disease."

More Information

Copyright © 2011 HealthDay. All rights reserved.

Powered by

jQuery UI Accordion - Default functionality

For life-long learning and continuing professional development, come to Lippincott's NursingCenter.

Nursing Jobs Plus
Featured Jobs
Recommended CE Articles

Blunt Chest Trauma
Journal of Trauma Nursing, November/December 2014
Expires: 12/31/2016 CE:2 $21.95

The School Age Child with Congenital Heart Disease
MCN, The American Journal of Maternal/Child Nursing, January/February 2015
Expires: 2/28/2017 CE:2.5 $24.95

Understanding multiple myeloma
Nursing Made Incredibly Easy!, January/February 2015
Expires: 2/28/2017 CE:2 $21.95

More CE Articles

Subscribe to Recommended CE

Recommended Nursing Articles

Comprehensive Care: Looking Beyond the Presenting Problem
Journal of Christian Nursing, January/March 2015
Free access will expire on March 2, 2015.

Pain and Alzheimer dementia: A largely unrecognized problem
Nursing Made Incredibly Easy!, January/February 2015
Free access will expire on February 16, 2015.

Glycemic control in hospitalized patients
Nursing2015 Critical Care, January 2015
Free access will expire on February 16, 2015.

More Recommended Articles

Subscribe to Recommended Articles

Evidence Based Practice Skin Care Network NursingCenter Quick Links What’s Trending Events